Persistent Negative Symptoms in Young People at Clinical High Risk of Psychosis Treated with an Italian Early Intervention Program: a Longitudinal Study

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 2024 Apr 26

PMID 38668766

Authors

Camilla Ricci

Emanuela Leuci

Emanuela Quattrone

Derna Palmisano

Pietro Pellegrini

Marco Menchetti

Simona Pupo

Lorenzo Pelizza

Affiliations

Soon will be listed here.

Abstract

Negative symptoms in CHR-P people are generally not responsive to treatments and commonly related to poorer functional outcome. However, less research attention has been dedicated to Persistent Negative Symptoms (PNS), defined as clinically stable negative symptoms of moderate severity evident for at least 6 months. This study aims to (a) determine the prevalence of PNS in a sample of young people at CHR-P; (b) investigate any association of PNS with functioning and clinical features; (c) examine longitudinal course of PNS across 2 years of follow-up and changes in PNS severity levels with specialized treatments. One Hundred Eighty CHR-P participants were recruited and were divided into CHR-P/PNS + and CHR-P/PNS- subgroups. The clinical assessments were based on the PANSS and the GAF and were conducted at baseline and every 12 months during the follow-up. Twenty four participants showed PNS at entry. Of them, 21 concluded the 2-year follow-up period. At baseline, the CHR-P/PNS + participants showed more educational and employment deficits, and more social and functioning impairment. During the follow-up, the CHR-P/PNS + subgroup had a significant longitudinal decrease in negative symptoms, which was specifically related to antidepressant treatment. CHR-P/PNS + subjects also showed a higher incidence of new hospitalization and a lower functional recovery over time. Our findings support that the persistence of negative symptoms in CHR-P people is longitudinally related to worse daily functioning and more severe clinical conditions that are at higher risk of hospitalization and are less responsive to specialized treatments.

References

Azzali S, Pelizza L, Scazza I, Paterlini F, Garlassi S, Chiri L . Examining subjective experience of aberrant salience in young individuals at ultra-high risk (UHR) of psychosis: A 1-year longitudinal study. Schizophr Res. 2022; 241:52-58. DOI: 10.1016/j.schres.2021.12.025. View

Schultze-Lutter F, Rahman J, Ruhrmann S, Michel C, Schimmelmann B, Maier W . Duration of unspecific prodromal and clinical high risk states, and early help-seeking in first-admission psychosis patients. Soc Psychiatry Psychiatr Epidemiol. 2015; 50(12):1831-41. DOI: 10.1007/s00127-015-1093-3. View

Sauve G, Brodeur M, Shah J, Lepage M . The Prevalence of Negative Symptoms Across the Stages of the Psychosis Continuum. Harv Rev Psychiatry. 2018; 27(1):15-32. DOI: 10.1097/HRP.0000000000000184. View

Devoe D, Lui L, Cannon T, Cadenhead K, Cornblatt B, Keshavan M . The impact of early factors on persistent negative symptoms in youth at clinical high risk for psychosis. Front Psychiatry. 2023; 14:1125168. PMC: 10244495. DOI: 10.3389/fpsyt.2023.1125168. View

Pelizza L, Leuci E, Quattrone E, Azzali S, Paulillo G, Pupo S . Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program. Early Interv Psychiatry. 2023; 18(2):71-81. DOI: 10.1111/eip.13434. View

Tran T, Spilka M, Raugh I, Strauss G, Bearden C, Cadenhead K . Negative Symptom Trajectories in Individuals at Clinical High Risk for Psychosis: Differences Based on Deficit Syndrome, Persistence, and Transition Status. Schizophr Bull Open. 2023; 4(1):sgad014. PMC: 10287168. DOI: 10.1093/schizbullopen/sgad014. View

Pelizza L, Paterlini F, Azzali S, Garlassi S, Scazza I, Pupo S . The approved Italian version of the comprehensive assessment of at-risk mental states (CAARMS-ITA): Field test and psychometric features. Early Interv Psychiatry. 2018; 13(4):810-817. DOI: 10.1111/eip.12669. View

Rutigliano G, Valmaggia L, Landi P, Frascarelli M, Cappucciati M, Sear V . Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. J Affect Disord. 2016; 203:101-110. DOI: 10.1016/j.jad.2016.05.053. View

Correll C, Schooler N . Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020; 16:519-534. PMC: 7041437. DOI: 10.2147/NDT.S225643. View

10.

Pelizza L, Maestri D, Leuci E, Quattrone E, Azzali S, Paulillo G . Individual psychotherapy can reduce suicidal ideation in first episode psychosis: Further findings from the 2-year follow-up of the 'Parma Early Psychosis' programme. Clin Psychol Psychother. 2021; 29(3):982-989. DOI: 10.1002/cpp.2678. View

11.

Poletti M, Pelizza L, Azzali S, Garlassi S, Scazza I, Paterlini F . Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study. Nord J Psychiatry. 2021; 76(2):129-137. DOI: 10.1080/08039488.2021.1942547. View

12.

Turner D, van der Gaag M, Karyotaki E, Cuijpers P . Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014; 171(5):523-38. DOI: 10.1176/appi.ajp.2013.13081159. View

13.

Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabe M . EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021; 64(1):e21. PMC: 8057437. DOI: 10.1192/j.eurpsy.2021.13. View

14.

McFarlane W . Family Interventions for Schizophrenia and the Psychoses: A Review. Fam Process. 2016; 55(3):460-82. DOI: 10.1111/famp.12235. View

15.

Pelizza L, Leuci E, Quattrone E, Azzali S, Paulillo G, Pupo S . Longitudinal evaluation on negative symptoms in young people at Ultra-High Risk (UHR) of psychosis: results from a 2-year follow-up study in a real-world care setting. Eur Arch Psychiatry Clin Neurosci. 2023; 273(8):1761-1771. DOI: 10.1007/s00406-023-01600-2. View

16.

Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A . Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018; 268(7):625-639. DOI: 10.1007/s00406-018-0869-3. View

17.

Valmaggia L, Stahl D, Yung A, Nelson B, Fusar-Poli P, McGorry P . Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychol Med. 2013; 43(11):2311-25. DOI: 10.1017/S0033291713000251. View

18.

Devoe D, Lu L, Cannon T, Cadenhead K, Cornblatt B, McGlashan T . Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study. Schizophr Res. 2020; 227:28-37. PMC: 7606256. DOI: 10.1016/j.schres.2020.04.004. View

19.

Yang Z, Lim K, Lam M, Keefe R, Lee J . Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. Schizophr Res. 2018; 201:85-90. DOI: 10.1016/j.schres.2018.05.024. View

20.

van der Gaag M, Nieman D, Rietdijk J, Dragt S, Ising H, Klaassen R . Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. 2012; 38(6):1180-8. PMC: 3494039. DOI: 10.1093/schbul/sbs105. View